Syed Rizvi, MD
Psychiatry · Lexington, KYNPI 1801089289
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by EMD Serono, Inc. at 51.9% of the total. Reporting peaked in 2023 at $8,928 and has fallen 96.5% since, to $309 in 2025. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $145.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$9K
- Otsuka America Pharmaceutical, Inc.$6K
- Stryker$718
- Neurocrine Biosciences, Inc.$282
- Alkermes, Inc.$243
- Johnson & Johnson$170
- plus $595 from 9 others
What the payments were for
- Consulting fees$8,51450%
- Speaking & faculty fees$5,69833%
- Travel & lodging$4773%
- Food & beverage$2,49114%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 8 | $8,915 |
| Otsuka America Pharmaceutical, Inc. | 34 | $6,260 |
| Stryker | 9 | $718 |
| Neurocrine Biosciences, Inc. | 11 | $282 |
| Alkermes, Inc. | 13 | $243 |
| Johnson & Johnson | 11 | $170 |
| Lundbeck LLC | 11 | $149 |
| Treace Medical Concepts, Inc. | 2 | $144 |
| Teva Pharmaceuticals USA, Inc. | 6 | $85 |
| Sunovion Pharmaceuticals Inc. | 4 | $80 |
| AbbVie(2 entities) | 5 | $70 |
| Indivior Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evobrutinib$8,514
- ABILIFY MAINTENA$5,881
- AUGMENT INJECTABLE$165
- ANCHORAGE$155
- INFINITY ADAPTIS$129
How this compares
$17,181 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 169 | $548,937 |
| AustedoDeutetrabenazine | 68 | $508,845 |
| Invega TrinzaPaliperidone Palmitate | 29 | $234,138 |
| IngrezzaValbenazine Tosylate | 27 | $190,070 |
| Abilify MaintenaAripiprazole | 45 | $131,617 |
| Risperdal ConstaRisperidone Microspheres | 83 | $90,079 |
| VraylarCariprazine Hcl | 29 | $40,104 |
| Clozapine | 243 | $29,996 |
| Aripiprazole | 328 | $21,173 |
| Divalproex Sodium | 319 | $14,967 |
| Lurasidone Hcl | 56 | $11,866 |
| Olanzapine | 302 | $9,994 |
| Quetiapine Fumarate | 301 | $8,207 |
| Divalproex Sodium ErDivalproex Sodium | 115 | $7,697 |
| Ziprasidone Hcl | 115 | $6,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $170 | $873,154281 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $85 | $508,84568 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $282 | $190,07027 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $6,260 | $131,61745 claims |
| AbbVieVraylar | $70 | $40,10429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Lexington
- Mark WrightLexington$637K
- Steven CroleyLexington$151K
- Jacob BishopLexington$56K
- Andrew CooleyLexington$47K
- Michelle LofwallLexington$11K
- Saeed HamidLexington$10K
- Getulio TovarLexington$5K
- Brian KeltyLexington$4K
- Andre FernandezLexington$4K
- Carmen PintoElizabethtown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.